1. What Inhibits Natural Killers' Performance in Tumour
- Author
-
Ines Papak, Elżbieta Chruściel, Katarzyna Dziubek, Małgorzata Kurkowiak, Zuzanna Urban-Wójciuk, Tomasz Marjański, Witold Rzyman, and Natalia Marek-Trzonkowska
- Subjects
T-Lymphocytes ,Organic Chemistry ,General Medicine ,Immunotherapy, Adoptive ,Catalysis ,Computer Science Applications ,Inorganic Chemistry ,Killer Cells, Natural ,Neoplasms ,Humans ,Immunotherapy ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy - Abstract
Natural killer cells are innate lymphocytes with the ability to lyse tumour cells depending on the balance of their activating and inhibiting receptors. Growing numbers of clinical trials show promising results of NK cell-based immunotherapies. Unlike T cells, NK cells can lyse tumour cells independent of antigen presentation, based simply on their activation and inhibition receptors. Various strategies to improve NK cell-based therapies are being developed, all with one goal: to shift the balance to activation. In this review, we discuss the current understanding of ways NK cells can lyse tumour cells and all the inhibitory signals stopping their cytotoxic potential.
- Published
- 2022